- Home
- WCN vs ALNY Comparison
WCN vs ALNY Comparison
Compare WCN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCN
- ALNY
- Stock Information
- Founded
- WCN 1997
- ALNY 2002
- Country
- WCN Canada
- ALNY United States
- Employees
- WCN N/A
- ALNY N/A
- Industry
- WCN Power Generation
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- WCN Utilities
- ALNY Health Care
- Exchange
- WCN Nasdaq
- ALNY Nasdaq
- Market Cap
- WCN 48.9B
- ALNY 40.4B
- IPO Year
- WCN 1998
- ALNY 2004
- Fundamental
- Price
- WCN $185.77
- ALNY $324.29
- Analyst Decision
- WCN Strong Buy
- ALNY Strong Buy
- Analyst Count
- WCN 16
- ALNY 23
- Target Price
- WCN $210.06
- ALNY $340.00
- AVG Volume (30 Days)
- WCN 816.3K
- ALNY 805.7K
- Earning Date
- WCN 07-23-2025
- ALNY 07-31-2025
- Dividend Yield
- WCN 0.67%
- ALNY N/A
- EPS Growth
- WCN N/A
- ALNY N/A
- EPS
- WCN 2.43
- ALNY N/A
- Revenue
- WCN $9,075,114,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- WCN $7.94
- ALNY $30.77
- Revenue Next Year
- WCN $7.09
- ALNY $30.51
- P/E Ratio
- WCN $76.86
- ALNY N/A
- Revenue Growth
- WCN 10.75
- ALNY 17.21
- 52 Week Low
- WCN $169.36
- ALNY $205.87
- 52 Week High
- WCN $201.66
- ALNY $327.05
- Technical
- Relative Strength Index (RSI)
- WCN 40.56
- ALNY 66.83
- Support Level
- WCN $185.32
- ALNY $315.00
- Resistance Level
- WCN $188.54
- ALNY $327.21
- Average True Range (ATR)
- WCN 2.61
- ALNY 7.70
- MACD
- WCN -0.14
- ALNY 0.19
- Stochastic Oscillator
- WCN 9.97
- ALNY 90.70
About WCN Waste Connections Inc.
Waste Connections is the third-largest integrated provider of traditional solid waste and recycling services in the North America, operating 113 active landfills (20 are exploration and production waste landfills and 16 are nonmunicipal waste landfills), 163 transfer stations, and 89 recycling operations. The firm serves residential, commercial, industrial, and energy end markets. Waste Connections entered the Canadian market with its 2016 merger with Progressive Waste. In 2024, 14% of consolidated revenue was generated from the firm's Canadian segment.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.